Fang J - Search Results

1

Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.

Yang Y, Sun J, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Ma R, Bi M, Ren X, Zhou J, Li B, Song Y, Feng J, Li J, He Z, Zhou R, Li W, Lu Y, Zhou H, Wang S, Sun L, Puig O, Mancao C, Peng B, Fang W, Xu W, Zhang L. Yang Y, et al. Among authors: fang w, fang j. J Thorac Oncol. 2021 Dec;16(12):2109-2120. doi: 10.1016/j.jtho.2021.07.015. Epub 2021 Aug 3. J Thorac Oncol. 2021. PMID: 34358724 Free article.

2

[Analysis of prognostic factors of 80 advanced NSCLC patients treated with gefitinib for more than 6 months].

Dai L, Fang J, Nie J, Hu W, Chen X, Han J, Tian G, Han S, Liu X. Dai L, et al. Among authors: fang j. Zhongguo Fei Ai Za Zhi. 2010 Nov;13(11):1050-5. doi: 10.3779/j.issn.1009-3419.2010.11.10. Zhongguo Fei Ai Za Zhi. 2010. PMID: 21081047 Free PMC article. Chinese.

3

[Concurrent versus sequential systemic chemotherapy and whole brain radiation therapy for brain matastases in non-small-cell lung cancer patients].

Jiang HF, Fang J, Ren J, DI LJ, Song GH, Che L, Yu J, Zhu YL. Jiang HF, et al. Among authors: fang j. Zhonghua Zhong Liu Za Zhi. 2011 Jan;33(1):58-62. Zhonghua Zhong Liu Za Zhi. 2011. PMID: 21575467 Clinical Trial. Chinese.

4

[A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer].

Huang Y, Liu Y, Zhou J, Xu N, Li B, Wu G, Fang J, Li K, Liu X, Liu W, Lu Y, Wang M, Liu W, Liang H, Zhang Y, Huang C, Wang S, Wang Y, Yu S, Chang J, Wang Z, Hu Z, Zhang L. Huang Y, et al. Among authors: fang j. Zhongguo Fei Ai Za Zhi. 2012 Oct;15(10):576-82. doi: 10.3779/j.issn.1009-3419.2012.10.03. Zhongguo Fei Ai Za Zhi. 2012. PMID: 23075681 Free PMC article. Clinical Trial. Chinese.

5

A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.

Lv C, Ma Y, Wu N, Yan S, Zheng Q, Sun Y, Li S, Fang J, Yang Y. Lv C, et al. Among authors: fang j. World J Surg Oncol. 2013 Mar 21;11:76. doi: 10.1186/1477-7819-11-76. World J Surg Oncol. 2013. PMID: 23517534 Free PMC article.

6

A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?

Lv C, An C, Feng Q, Ma Y, Li S, Wang J, Zhang J, Wang X, Yan S, Fang J, Wang Y, Tan F, Yang Y. Lv C, et al. Among authors: fang j. Clin Lung Cancer. 2015 Nov;16(6):e173-81. doi: 10.1016/j.cllc.2015.04.002. Epub 2015 Apr 20. Clin Lung Cancer. 2015. PMID: 25958850 Free article.

7

[Effects of Local Radiation Combined with Chemotherapy in the treatment of  Patients with Extensive-stage Small Cell Lung Cancer].

Wu D, Fang J, Nie J, Dai L, Chen X, Zhang J, Hu W, Han J, Ma X, Tian G, Han S, Long J, Wang Y. Wu D, et al. Among authors: fang j. Zhongguo Fei Ai Za Zhi. 2015 May;18(5):272-9. doi: 10.3779/j.issn.1009-3419.2015.05.04. Zhongguo Fei Ai Za Zhi. 2015. PMID: 25975297 Free PMC article. Chinese.

8

Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics.

Zhang J, Gao J, Li Y, Nie J, Dai L, Hu W, Chen X, Han J, Ma X, Tian G, Wu D, Shen L, Fang J. Zhang J, et al. Among authors: fang j. Thorac Cancer. 2015 Jul;6(4):534-8. doi: 10.1111/1759-7714.12247. Epub 2015 Mar 5. Thorac Cancer. 2015. PMID: 26273411 Free PMC article.

9

Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer.

Hu W, Fang J, Nie J, Dai L, Zhang J, Chen X, Ma X, Tian G, Wu D, Han S, Han J, Wang Y, Long J. Hu W, et al. Among authors: fang j. Medicine (Baltimore). 2016 Jul;95(28):e4183. doi: 10.1097/MD.0000000000004183. Medicine (Baltimore). 2016. PMID: 27428214 Free PMC article.

10

Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC.

Wu D, Liang L, Nie L, Nie J, Dai L, Hu W, Zhang J, Chen X, Han J, Ma X, Tian G, Han S, Long J, Wang Y, Zhang Z, Xin T, Fang J. Wu D, et al. Among authors: fang j. Asia Pac J Clin Oncol. 2018 Dec;14(6):446-452. doi: 10.1111/ajco.12870. Epub 2018 Mar 24. Asia Pac J Clin Oncol. 2018. PMID: 29573236

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12,381 results

Search Page

Filters